Research programme: tissue factor/factor VIIa complex inhibitors - BioCryst/Sunol MolecularAlternative Names: BCX 3607; BCX 3891
Latest Information Update: 02 Apr 2008
At a glance
- Originator BioCryst Pharmaceuticals; Sunol Molecular Corporation
- Developer BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Factor VIIa inhibitors; Thromboplastin inhibitors; Tissue factor-factor VIIa complex inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Coronary disorders; Thrombosis